Monoclonal antibody infusions blocking complement C5 for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Administered in hematology units by infusion specialists. Developed by biotech firms, purchased via high-cost drug programs for rare disease treatment centers.